卡培他滨、奈达铂同步化疗联合放疗治疗老年食管癌临床研究

Clinical research on capecitabine and nedaplatin combined with chemoradiotherapy in the treatment of the elderly patients with esophageal cancer

目的评价同步放化疗在老年食管癌治疗中的应用价值。方法 87例老年食管癌患者随机分为同步放化疗组(42例)和单独放疗组(45例),随访2组临床疗效及毒副反应。结果同步放化组和单放组的总有效率(CR+PR)分别为92.9%、77.8%,2组比较差异有统计学意义(P<0.05);同步放化组和单放组的1﹑2年生存率分别为85.7%、59.5%,66.7%、37.8%,生存率比较差异有统计学意义(P<0.05);同步放化疗组的毒副反应高于单独放疗组(P<0.05)。结论同步放化疗能提高老年食管癌患者总有效率及1、2年生存率,但亦显著增加了放疗副反应。

Objective To evaluate the efficacy of capecitabine and nedaplatin combined with chemoradiotherapy in the treatment of the elderly patients with esophageal cancer. Methods 87 patients were randomly divided into concurrent chemoradiotherapy group（42 patients） and radiotherapy group（45 patients）. The chemoradiotherapy group was treated with concurrent radiotherapy combined with chemotherapy while the radiotherapy group was treated with radiotherapy only. Results The overall efficacy（CR ＋ PR） rates of concurrent chemoradiotherapy group and control group were 92. 9%and 77. 8,the difference was significant between the two groups（P〈0. 05）. The survival rate of concurrent group after 1 year and 2 years was higher than that in the control group（85. 7%,59. 5% in 1year vs 66. 7%,37. 8% in 2 years respectively）. And the difference in toxicity was significant between the two groups with higher toxicity in the concurrent chemoradiotherapy group than in the control group（P〈0. 05）. Conclusion The concurrent chemoradiotherapy in the treatment of the elderly with esophageal cancer can improve the overall efficacy rates and 1,2 year survival rates,but the toxicity was significantly higher.